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Objectives: Asthma is a chronic respiratory disease with a high burden of disease 
and a relevant Public Health problem. The active patient active involvement is cru-
cial to yield the proper disease control. The aim of the study was to assess treatment 
adherence with the combination of inhaled corticosteroids (ICS) and long-acting 
beta-2 agonists (LABA), known as ICS/LABA, in the same fixed dose combination 
inhalers, depending on the inhaler device used: pressurized metered dose inhalers 
(pMDI) or dry powder inhalers (DPI), for the treatment of asthma in a real world back-
groung. Additionally asthma exacerbations, resources consumption, and associated 
costs were recorded. MethOds: An observational, retrospective study was per-
formed. Patients aged ≥ 18 years, diagnosed with asthma, and who initiated an ICS/
LABA combination treatment during 2007-2011. Patients follow-up lasted for 3 years. 
Two treatment groups of patients were identified and assessed, depending on the 
inhaler device used: pMDI or DPI. The main measures were: adherence (posession 
drug ratio), persistence, asthma severity, ICS/LABA combinations used, exacerba-
tions, resources use and their costs (direct and indirect costs). Multivariate methods 
were used for the variables correction, with a p significance degree ‹0.05. Results: 
We included 2,082 asthma patients. Mean age 52.6 years, 65.3% female: 566 patients 
(27.2%) received an pMDI and 1,516 patients (72.8%) received an DPI. Patients who 
used and pMDI device showed a higher treatment adherence (RPM: 82.9% vs 80.8%, 
p< 0.05), fewer number of exacerbations (17.7% vs 24.9%, p< 0.001), and a lower health 
cost (€ 2,531 vs € 3,020, p< 0.001). cOnclusiOns: Despite the limitations of the study, 
patients with asthma who started an ICS/LABA therapy who were treated with an 
pMDI device had higer adherence rates, better health outcomes and lower health 
costs for the Spanish National Health System.
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Objectives: Long-term treatment adherence of patients with multiple sclerosis 
(MS) treated with injectable drugs is a general concern. Closely monitoring patients’ 
therapy adherence may be beneficial. The objective of this study was to assess treat-
ment adherence of MS patients treated with the injectable drug interferon beta-1a, 
administered with the RebiSmart system. MethOds: A retrospective observational 
study was conducted, monitoring patients’ treatment adherence with the RebiSmart 
system in their normal treatment setting. The RebiSmart is an electronic, multidose 
auto-self-injection device aimed to improve assessment of treatment adherence. It 
contains a cartridge including a weekly dose. The device can accurately record time 
and dosage of each administered injection. Patients can view their own dosing log. 
Moreover, patients’ physicians can download the information providing an objective 
record of treatment adherence. To determine treatment adherence with RebiSmart, 
anonymous patient-level data of Dutch and German patients were extracted from 
the RebiSmart systems on dosing, time, and number of administrations over a five-
year time-period. Adherence was defined as taking > 80% of the treatment doses 
according to the schedule the doctor prescribed. Results: Data was collected from 
1832 patients (81% German, 73% females, average age 40.1 years). In total, 95% of 
the cartridges were used completely, indicating low drug spillage. Over the com-
plete observational period, 91% of all doses were administered according to doctor’s 
prescription. Examining individual adherence, 83% of the patients were considered 
adherent the whole period using interferon beta-1a. Results from Dutch and German 
patients were similar. cOnclusiOns: Patients using the RebiSmart device in this 
study had a considerably higher adherence level than the approximately 60% adher-
ence indicated by previous research studying adherence of MS patients on disease-
modifying drugs. Drug spillage was low. Using an auto-injection device monitoring 
patients’ treatment behavior may positively contribute to treatment adherence. 
This should be further investigated in comparative research.
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Objectives: To identify the impact of delivery device of inhaled corticosteroids and 
long-acting β 2-agonist (ICS/LABA) on asthma medication compliance, and inves-
tigate other factors associated with poor compliance. MethOds: We conducted 
a retrospective and multicentre study based on a review of medical registries of 
asthmatic patients treated with ICS/LABA combinations (n= 2,213) whose medical 
devices were either dry powder inhalers (DPI) or pressurized metered-dose inhalers 
(pMDI). Medication compliance included persistence outcomes through 18 months 
and medication possession ratios. Data on potential confounders of treatment com-
pliance such as asthma exacerbations, comorbidities, demographic characteristics 
and healthcare resource utilization were also explored. Results: The probability of 
asthma medication compliance in case of DPI was lower compared to pMDI, which 
suggest that inhaler devices condition inhalation therapies. There were additional 
confounding factors that were considered as explanatory variables of compliance. 
A worse measure of airflow obstruction (FEV1), comorbidities and visiting the GP 
more than once per month decreased the probability of compliance. Within comor-
bidities, alcoholism was positively associated with compliance. Patients of 29-39, 
40-50 and 51-61 age groups or suffering from more than 2 exacerbations during the 
study period were more likely to comply with their medication regime. We identified 
differences among DPI devices and Accuhaler® device impacted negatively greater 
on compliance compared to other DPIs. We found that GP consultations reduced 
the probability of medication compliance for patients treated with Formoterol/
ogy laboratory standard working days. The time required to test one sample was 
timed for each methodology separately and the pertaining costs were calculated. 
The working dimension of the two technologies and of the instruments needed 
was also measured. Results: The hands-on time for SISH was 76.25% lower than 
the implementation of FISH and the dedicated spaces needed to carry out the SISH 
test was 45.27% less than FISH. Lastly, the costs of using an automated SISH system 
were lower than FISH. cOnclusiOns: As a consequence of a significant reduc-
tion of laboratory personnel working hours, medical resources used and pathology 
laboratory spaces, the use of SISH technique to identify HER2 status is a cost-saving 
alternative to FISH from the perspective of the pathology laboratory.
MeDIcal DevIce/DIagnosTIcs – Patient-reported outcomes & Patient  
Preference studies
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Objectives: Chronic Obstructive Pulmonary Disease (COPD) is a chronic respira-
tory disease with a high burden of disease and a relevant Public Health problem. 
The active patient active involvement is crucial to yield the proper disease con-
trol. The aim of the study was to assess treatment adherence with the combi-
nation of inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA), 
known as ICS/LABA, in the same fixed dose combination inhalers, depending 
on the inhaler device used: pressurized metered dose inhalers (pMDI) or dry 
powder inhalers (DPI), for the treatment of COPD in a real world backgroung. 
Additionally COPD exacerbations, resources consumption, and associated costs 
were recorded. MethOds: An observational, retrospective study was performed. 
Patients aged ≥ 40 years, diagnosed with COPD, and who initiated an ICS/LABA 
combination treatment during 2007-2011. Patients follow-up lasted for 3 years. 
Two treatment groups of patients were identified and assessed, depending on the 
inhaler device used: pMDI or DPI. The main measures were: adherence (posession 
drug ratio), persistence, asthma severity, ICS/LABA combinations used, exacer-
bations, resources use and their costs (direct and indirect costs). Multivariate 
methods were used for the variables correction, with a p significance degree 
‹0.05. Results: We included 1,418 COPD patients. Mean age 72.1 years, 82.7% male: 
594 patients (41.9%) received an pMDI and 824 patients (58.1%) received an DPI. 
Patients who used and pMDI device showed a higher treatment adherence (RPM: 
83.3% vs 79.9%, p< 0.05), fewer number of exacerbations (40.1% vs 48.2%, p= 0.002), 
and a lower health cost (€ 3,943 vs € 4,621, p< 0.001). cOnclusiOns: Despite the 
limitations of the study, patients with COPD who started an ICS/LABA therapy 
who were treated with an pMDI device had higer adherence rates, better health 
outcomes and lower health costs for the Spanish National Health System.
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Objectives: This study aims to identify factors associated with poor compliance 
to COPD treatment in patients receiving a fixed-dose combination (FDC) of inhaled 
corticosteroids and long-acting β 2-agonist(ICS/LABA), focusing on the importance 
of inhaler devices. MethOds: We conducted a retrospective and multicentre 
study based on a review of medical registries between 2007-2012 of COPD patients 
(n= 1,263) treated with ICS/LABA FDC, whose medical devices were either dry powder 
inhalers (DPI) or pressurized metered-dose inhalers (pMDI). Medication compli-
ance included persistence outcomes through 18 months and medication posses-
sion ratios. Data on exacerbations, comorbidities, demographic characteristics and 
healthcare resource utilization were also included as confounders of medication 
compliance. Results: The analyses revealed that COPD patients whose medication 
was delivered by a DPI were less likely to comply with their treatment compared 
to patients with pMDI, after adjusting for confounding factors, especially active 
ingredients. Younger groups of patients were less likely to comply with their medi-
cation compared to the oldest group. Smoker men were less likely to comply with 
their medication compared to women and non-smokers. Comorbidities decreased 
the probability of treatment compliance. Those patients that visited their GP once 
a month were more likely to comply with their medication regimen, however sub-
optimal compliance was more likely to occur among those patients who visited 
more than 3 times per month their GP. We also found that worsening of COPD is 
negatively associated with compliance. cOnclusiOns: According to this study, 
inhaler devices influence patients’ compliance for long-term COPD medication. We 
also found that DPIs delivering ICS/LABA FDC had a negative impact on medica-
tion compliance. Patients’ clinic and socioeconomic characteristics were associated 
with compliance.
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life. When possible, meta-analysis was performed, evaluating the presence of het-
erogeneity and risk of publication bias. Otherwise, descriptive analysis of the avail-
able data was done. Results: Of the 10.348 original references scanned, 17 studies 
were finally selected, 7 experimental and 10 analytical. The population included 
was mainly adults, with type 2 diabetes. Important risk of bias was found in all of 
the articles, particularly the experimental ones. Meta-analysis was performed for 
glycemic control, hypoglycemia, adherence and persistence. Pen devices showed 
better results in mean HbA1c change, frequency of hypoglycemia, adherence and 
persistence compared to vial and syringes. No difference was observed in number 
of patients achieving < 7% of HbA1c. Studies regarding preference showed a clear 
tendency favorable to pen devices, but measurement methods were generally not 
well validated. One study on quality of life showed improvements in some subscales 
of SF-36. cOnclusiOns: There is evidence that pen devices offer benefits regarding 
glycemic control, hypoglycemia, adherence, persistence, patient preference and 
quality of life compared to vial and syringes for insulin administration. However, 
data had considerable risk of bias, more methodologically sound studies are needed.
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Objectives: Several GLP-1 receptor agonists are available as weekly injections for 
treatment of type 2 diabetes. These medications vary in their injection delivery 
systems, and these differences could impact quality of life and patient preference. 
The purpose of this study was to estimate utilities associated with injection deliv-
ery systems for weekly GLP-1 therapies. MethOds: Participants diagnosed with 
type 2 diabetes in the UK (Inverness, Portree, Edinburgh, London) valued health 
states in time trade-off (TTO) interviews. The health states (drafted based on lit-
erature, device instructions for use, and clinician interviews) had identical descrip-
tions of type 2 diabetes, but differed in description of the treatment process. One 
health state described an oral only treatment regimen (i.e., tablets), while six 
health states described oral treatment plus a weekly injection. The injection health 
states differed in the treatment administration process (e.g., requirements for 
reconstituting the medication, waiting during medication preparation, and nee-
dle handling). Results: A total of 209 participants completed interviews (57.4% 
male; mean age = 60.4y; 150 patients from Scotland and 59 from London). The 
mean (SD) utility of the oral treatment health state was 0.89 (0.12), and all injec-
tion health states had significantly (all p < 0.01) lower utilities ranging from 0.86 
(reconstitution, waiting, and handling) to 0.88 (weekly injection without any of the 
three treatment administration requirements). Utility differences among the injec-
tion health states suggest that each administration requirement had a small but 
measureable disutility (i.e., negative utility difference). Disutility values include 
-0.004 (reconstitution), -0.004 (needle handling), -0.010 (reconstitution, needle 
handling), and -0.020 (reconstitution, waiting, needle handling). cOnclusiOns: 
Findings suggest that the TTO method may be used to quantify preferences among 
different injection treatment processes. It may be useful to incorporate these dif-
ferences into cost-utility models comparing among weekly injectable treatment 
for patients with type 2 diabetes.
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Objectives: Glucose monitoring is particularly important for patients with diabetes 
treated with insulin. Conventional self-monitoring of blood glucose (SMBG) requires 
a blood sample, typically obtained by pricking the finger with a lancing device. A 
new device (FreeStyle Libre™ flash glucose monitoring system) has been developed 
to monitor glucose levels with a sensor worn on the arm, without requiring blood 
samples. This study estimated utility associated with these two glucose monitoring 
approaches so that the values may be used in cost-utility models. MethOds: In 
time trade-off (TTO) interviews, general population participants in the UK (London, 
Edinburgh) valued two health states which were drafted based on literature and 
clinician interviews. The health states had identical descriptions of diabetes and 
insulin treatment, but differed in glucose monitoring with either the FreeStyle 
Lite™ (SMBG) or the FreeStyle Libre (flash monitoring) system. Results: A total 
of 209 participants completed interviews (51.7% female; mean age = 42.1 y). Mean 
(SD) utilities were 0.851 (0.140) for SMBG and 0.882 (0.121) for flash monitoring 
(significant difference between the mean utilities; t = 8.3; p < 0.0001). Of the 209 
participants, 78 (37.3%) had a higher utility for flash monitoring, two (0.96%) had a 
higher utility for SMBG, and 129 (61.7%) had the same utility for both health states. 
The mean score on a seven-point preference scale ranging from strongly prefer flash 
monitoring (1) to strongly prefer SMBG (7) indicates that the participants generally 
preferred the flash monitoring system (mean = 1.8; SD = 1.5). cOnclusiOns: The 
flash monitoring system was associated with significantly greater utility than SMBG. 
This difference can be used in cost-utility models, comparing the value of glucose 
monitoring devices for patients with diabetes. This study also demonstrates that the 
TTO method may be used to quantify preferences for medical devices.
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Objectives: Analysis of acceptability and effectiveness of upper limb rehabilitation 
treatments based on two robotic systems in stroke patients. MethOds: Two specific 
Budesonide combination. For retired patients, visiting the GP increased the probabil-
ity of medication compliance. cOnclusiOns: We concluded that inhaler devices 
influence patients’ compliance for long-term asthma medication. The impact of 
DPI on medication compliance was negative. We also identified some confounders 
of medication compliance such as patient’s age, severity of asthma, comorbidities 
and healthcare costs.
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Objectives: This single-site, cross-over study evaluated device mastery with dry 
powder inhalers, Spiromax®, Easyhaler® and Turbuhaler®. MethOds: Healthy 
inhaler-naïve participants aged ≥ 18 years (N= 120) were observed using each of 
the three empty devices (Spiromax, Easyhaler, and Turbuhaler) in a counter-bal-
anced order. To evaluate the proportion of participants achieving device mastery 
(defined as an absence of health care professional [HCP] observed errors), a three 
step approach was used: 1) intuitive use (no instructions), 2) use after reading the 
patient information leaflet (PIL) user instructions and 3) use after HCP instructions. 
Trained HCPs monitored use and recorded errors based on device-specific handling 
error checklists. Results: During steps 1 and 2, respectively, more participants 
used Spiromax without error (37.5% and 93.3%; p< 0.001) compared with Easyhaler 
(0% and 58.3%) and Turbuhaler (9.2% and 76.7%); performance level was high (> 95%) 
with all devices during step 3. The mean proportion of errors committed by partici-
pants in steps 1 and 2 was lower with Spiromax (12.4%, 0.8%; p< 0.001) compared 
with Easyhaler (18.7%, 5.0%) and Turbuhaler (17.6%, 2.8%); the proportion of errors 
for each device was similar in step 3 (0.1%, 0.5%, 0.1%, respectively). The most com-
mon errors in step 1 were related to orientation for Spiromax (51.3%), shaking for 
Easyhaler (95.8%), and priming for Turbuhaler (55.8%). All findings were independent 
of age, gender, and education level. cOnclusiOns: Spiromax was associated with 
higher levels of device mastery evidenced by intuitive use (no instructions) or PIL 
information, and fewer errors compared with Easyhaler and Turbuhaler. The most 
common errors associated with Spiromax were related to orientation. Assessing 
device mastery and providing training can improve drug effectiveness which may 
affect adherence and overall treatment costs.
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Objectives: Patient preference and overall satisfaction with their inhaler is cor-
related with improved adherence, better clinical outcomes and reduced costs. 
This single-site, cross-over study evaluated preference with dry powder inhal-
ers, Spiromax®, Easyhaler® and Turbuhaler®. MethOds: Healthy inhaler-naïve 
participants aged ≥ 18 years (N= 120) were observed using each of the three empty 
devices (Spiromax, Easyhaler, and Turbuhaler) in a counter-balanced order. A three 
step approach was used: 1) intuitive use (no instructions), 2) use after reading the 
patient information leaflet (PIL) user instructions, and 3) use after health care 
professional instructions. Devices were rated using a device preference question-
naire after participants completed the three steps with each device. Participants 
were also asked to rate their satisfaction (on a scale from 1 [unsatisfactory] to 
5 [excellent]) with the following features: 1) overall ease of use, 2) quality of PIL 
instructions, 3) preparing the dose, 4) inhaling procedure, and 5) clarity of dose 
counter. Results: Spiromax was rated as the easiest device to use by 73.1% of 
participants, and 71.4% reported that if prescribed an inhaler they would prefer 
Spiromax. In comparison, 12.6% rated Easyhaler and 14.3% rated Turbuhaler as 
easiest to use; 16.8% and 11.8% would prefer Easyhaler and Turbuhaler, respec-
tively, if prescribed an inhaler. Participants rated Spiromax significantly higher 
compared to both Easyhaler and Turbuhaler (p< 0.001 for all comparisons) for all 
features except inhaling procedure, where no differences were found. Differences 
between Easyhaler and Turbuhaler were not significant with regards to any of the 
features analyzed except quality of PIL instructions, where Turbuhaler received 
higher ratings (p< 0.003), and clarity of the counter, where Easyhaler received 
higher ratings (p< 0.015). cOnclusiOns: This study suggests that, if prescribed 
an inhaler product, device-naïve users prefer Spiromax and find it to be more 
intuitive in comparison to Easyhaler and Turbuhaler.
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Objectives: Studies suggest that “pen” devices offer advantages over traditional 
vial and syringe method for insulin administration. Our purpose was to evalu-
ate their efficacy safety and patient preference through a systematic review and 
meta-analysis. MethOds: A systematic review was performed using an expert-
approved PICO question, in 8 different databases. References were screened by 
two independent investigators. Primary observational or experimental full articles 
comparing pen devices with vial and syringes for insulin administration in adults 
with diabetes mellitus were included (except gestational diabetes). Manual search 
for additional references was performed on selected articles. Risk of bias was evalu-
ated using the appropriate tools. We collected data on glycosylated hemoglobin 
(HbA1c), hypoglycemia, adherence, persistence, patient preference and quality of 
